Install
We provide information, research, news and interviews from the emergent psychedelic sector in one place.
- 4articles · 30d
- 4+ day agolatest article
- Aug 18, 2026earliest in window
- 75%with images
- 329avg words
- Medical 4
- Health & Wellness 3
- Health 2
- Arts, Culture, Entertainment & Media 1
- Business & Industrial 1
- Economy, Business & Finance 1
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
4+ day, 2+ hour ago (353+ words) 🎟️ Join us at The Psychedelic Healthcare Forum in NYC In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its “new framework for psychedelic drugs”. The four agency staffers kick off the…...
Scoop: Johnson & Johnson to Lead Delix Therapeutics???? $85M Series C
3+ week, 5+ day ago (702+ words) 🎟️ Join us at The Psychedelic Business Forum in NYC Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round at a $190M pre-money valuation, according to documents reviewed by Psychedelic Alpha. Note: Audio versions of our articles are…...
Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development
3+ week, 6+ day ago (190+ words) 🎟️ Join us at The Psychedelic Business Forum in NYC This interview took place in May 2026. It has been edited for length and clarity. For the longest time, I felt there was something wrong with the idea that traditional antidepressants increase…...